Skip to main content
NASDAQ:GALT

Galectin Therapeutics Stock Forecast, Price & News

$4.23
+0.02 (+0.48 %)
(As of 05/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.03
$4.50
50-Day Range
$2.03
$5.10
52-Week Range
$1.82
$5.70
Volume863,087 shs
Average Volume1.88 million shs
Market Capitalization$241.77 million
P/E RatioN/A
Dividend YieldN/A
Beta2.04
30 days | 90 days | 365 days | Advanced Chart
Receive GALT News and Ratings via Email

Sign-up to receive the latest news and ratings for Galectin Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Galectin Therapeutics logo

About Galectin Therapeutics

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is (GR-MD-02) belapectin galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GALT
CUSIPN/A
Phone678-620-3186
Employees6
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Book Value$0.76 per share

Profitability

Net Income$-13,290,000.00

Debt

Price-To-Earnings

Miscellaneous

Market Cap$241.77 million
Next Earnings Date5/17/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.41 out of 5 stars

Medical Sector

685th out of 2,044 stocks

Pharmaceutical Preparations Industry

317th out of 769 stocks

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Galectin Therapeutics (NASDAQ:GALT) Frequently Asked Questions

Is Galectin Therapeutics a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Galectin Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Galectin Therapeutics stock.
View analyst ratings for Galectin Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Galectin Therapeutics?

Wall Street analysts have given Galectin Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Galectin Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Galectin Therapeutics' next earnings date?

Galectin Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, May 17th 2021.
View our earnings forecast for Galectin Therapeutics
.

How were Galectin Therapeutics' earnings last quarter?

Galectin Therapeutics Inc. (NASDAQ:GALT) posted its quarterly earnings data on Tuesday, March, 30th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.02.
View Galectin Therapeutics' earnings history
.

How has Galectin Therapeutics' stock price been impacted by COVID-19?

Galectin Therapeutics' stock was trading at $1.99 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, GALT shares have increased by 112.6% and is now trading at $4.23.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for GALT?

1 brokers have issued 12-month price targets for Galectin Therapeutics' stock. Their forecasts range from $14.00 to $14.00. On average, they anticipate Galectin Therapeutics' stock price to reach $14.00 in the next year. This suggests a possible upside of 231.0% from the stock's current price.
View analysts' price targets for Galectin Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Galectin Therapeutics' key executives?

Galectin Therapeutics' management team includes the following people:
  • Mr. Joel Lewis, Pres, CEO & Director (Age 51)
  • Mr. Jack W. Callicutt CPA, CPA, CFO, Treasurer & Sec. (Age 54)
  • Dr. Harold H. Shlevin, Consultant & Director (Age 71)
  • Robert Tritt, Gen. Counsel
  • Dr. Eliezer Zomer, Exec. VP of Manufacturing & Product Devel. (Age 74)
  • Ms. Beth Knowles, Exec. Assistant & Officer Mang.

Who are some of Galectin Therapeutics' key competitors?

What other stocks do shareholders of Galectin Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galectin Therapeutics investors own include Sorrento Therapeutics (SRNE), Catalyst Pharmaceuticals (CPRX), Viking Therapeutics (VKTX), Exelixis (EXEL), Progenics Pharmaceuticals (PGNX), Rigel Pharmaceuticals (RIGL), TherapeuticsMD (TXMD), Novavax (NVAX), Verastem (VSTM) and Immunomedics (IMMU).

What is Galectin Therapeutics' stock symbol?

Galectin Therapeutics trades on the NASDAQ under the ticker symbol "GALT."

Who are Galectin Therapeutics' major shareholders?

Galectin Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (4.59%), Geode Capital Management LLC (1.13%), Northern Trust Corp (0.74%), Renaissance Technologies LLC (0.54%), JPMorgan Chase & Co. (0.18%) and Bank of New York Mellon Corp (0.17%). Company insiders that own Galectin Therapeutics stock include Fund LP 10X, Gilbert F Amelio, Jack W Callicutt, Kevin D Freeman and Richard E Uihlein.
View institutional ownership trends for Galectin Therapeutics
.

Which institutional investors are selling Galectin Therapeutics stock?

GALT stock was sold by a variety of institutional investors in the last quarter, including D.A. Davidson & CO., Northern Trust Corp, Bank of New York Mellon Corp, Neuberger Berman Group LLC, JPMorgan Chase & Co., and Wedbush Securities Inc.. Company insiders that have sold Galectin Therapeutics company stock in the last year include Fund LP 10X, and Gilbert F Amelio.
View insider buying and selling activity for Galectin Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Galectin Therapeutics stock?

GALT stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, BlackRock Inc., Barclays PLC, Occudo Quantitative Strategies LP, Bank of Montreal Can, Dimensional Fund Advisors LP, and Geode Capital Management LLC. Company insiders that have bought Galectin Therapeutics stock in the last two years include Jack W Callicutt, Kevin D Freeman, and Richard E Uihlein.
View insider buying and selling activity for Galectin Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Galectin Therapeutics?

Shares of GALT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Galectin Therapeutics' stock price today?

One share of GALT stock can currently be purchased for approximately $4.23.

How much money does Galectin Therapeutics make?

Galectin Therapeutics has a market capitalization of $241.77 million. The company earns $-13,290,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis.

How many employees does Galectin Therapeutics have?

Galectin Therapeutics employs 6 workers across the globe.

What is Galectin Therapeutics' official website?

The official website for Galectin Therapeutics is www.galectintherapeutics.com.

Where are Galectin Therapeutics' headquarters?

Galectin Therapeutics is headquartered at 4960 PEACHTREE INDUSTRIAL BLVD. SUITE 240, NORCROSS GA, 30071.

How can I contact Galectin Therapeutics?

Galectin Therapeutics' mailing address is 4960 PEACHTREE INDUSTRIAL BLVD. SUITE 240, NORCROSS GA, 30071. The company can be reached via phone at 678-620-3186 or via email at [email protected]


This page was last updated on 5/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.